A Phase 3 interventional study of Ceftobiprole medocaril in Neonatal Sepsis, sponsored by Basilea Pharmaceutica. Completed at 14 sites in 8 countries. Open to participants aged 3 Days to 3 Months. Per ClinicalTrials.gov, last updated 2025-07-28.
Sponsored by Basilea Pharmaceutica · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluated the safety, pharmacokinetics and efficacy of ceftobiprole in term and pre-term newborn babies and infants up to 3 months of age with late-onset sepsis (LOS). Ceftobiprole is an antibiotic which belongs to a group of medicines called 'cephalosporin antibiotics'. It is approved for its use to treat adults and children with pneumonia in many European and non-European countries.
This was a multicenter, open-label, single-arm, multiple-dose study of intravenous (IV) ceftobiprole medocaril (prodrug of the active moiety ceftobiprole). It could be combined with ampicillin and/or an aminoglycoside based on the Investigator's judgement according to manufacturer's instructions and/or local standard of care.
Following screening, ceftobiprole was administered as a 2-hour infusion at a dose of 7.5 mg/kg every 12 hours to 15 mg/kg every 8 hours, depending on age and weight.
The target treatment duration was 3-10 days, which could be extended to 14 days if considered clinically necessary by the Investigator.
193 studies on the registry are indexed under Neonatal Sepsis; 42 are open to participants now.
This study's enrollment of 9 is below the median of 182 across 103 interventional studies indexed under Neonatal Sepsis.
Browse Neonatal Sepsis studies →Basilea Pharmaceutica is the lead sponsor of 60 studies on the registry; 7 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ceftobiprole medocaril: 7.5 mg/kg to 15 mg/kg
Drug: Ceftobiprole medocaril
Ceftobiprole medocaril: 7.5 mg/kg every 12 hours to 15 mg/kg every 8 hours, administered IV as a 2-hour infusion.
Number of Patients With Adverse Events (AEs)
Number of patients with AEs, serious adverse events (SAEs), AEs leading to discontinuations and AEs of special interest
Time frame: Up to 5-7 weeks
Maximum Observed Plasma Concentration (Cmax) of Ceftobiprole, Ceftobiprole Medocaril, and Open-ring Metabolite
Observed pharmacokinetic parameter Cmax of ceftobiprole (the active moiety), its pro-drug ceftobiprole medocaril and the open-ring metabolite in term and pre-term neonates with post-natal age up to 3 months
Time frame: On treatment Day 3 prior to and 2, 4, and 8 hours after the start of the first ceftobiprole infusion of the day
Number of Patients With a Clinical Response
Clinical cure rate at the end of treatment (EOT) at day 3-14 and test of cure (TOC) at 7-14 days after last ceftobiprole dose visits in the Intent-to-Treat (ITT) population
Time frame: Up to 28 days
Number of Participants With Improved Signs and Symptoms of Late Onset Sepsis (LOS)
Improved signs and symptoms of LOS (including fever, hypothermia, abnormal heart rate, signs of impaired circulation, petechial rash or sclerema neonatorum, respiratory distress, gastrointestinal distress, irritability, lethargy and/or muscular or arterial hypotonia) assessed at Day 3, EOT, and TOC visits (ITT) populations.
Time frame: Up to 28 days
Number of Patients With a Microbiological Response
Microbiological eradication or presumed eradication rate at the EOT and TOC visits.
Time frame: Up to 28 days
Treatment was administered in hospital setting
| Milestone | Pre-term Neonates | Term Neonates |
|---|---|---|
| Started | 6 | 3 |
| Completed | 4 | 2 |
| Not completed | 2 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Due to investigator absence | 1 | 0 |
| Withdrew: Cerebrospinal fluid test positive for s. aureus | 1 | 0 |
Number of patients with AEs, serious adverse events (SAEs), AEs leading to discontinuations and AEs of special interest
| Participants | Pre-term Neonates | Term Neonates |
|---|---|---|
| Any AE | 3 | 3 |
| Study-drug-related AE | 0 | 0 |
| SAE | 1 | 1 |
| Study-drug-related SAE | 0 | 0 |
| AE leading to treatment discontinuation | 0 | 1 |
| AE of special interest | 1 | 1 |
Observed pharmacokinetic parameter Cmax of ceftobiprole (the active moiety), its pro-drug ceftobiprole medocaril and the open-ring metabolite in term and pre-term neonates with post-natal age up to 3 months
| μg/mL | Pre-term Neonates | Term Neonates |
|---|---|---|
| Ceftobiprole | 17.2 (11.0 to 22.6) | 28.4 (19.1 to 33.8) |
| Ceftobiprole medocaril | 0.585 (0.276 to 5.70) | 0.552 (0.376 to 2.59) |
| Open-ring metabolite | 1.18 (0.624 to 1.69) | 1.68 (0.998 to 2.06) |
Clinical cure rate at the end of treatment (EOT) at day 3-14 and test of cure (TOC) at 7-14 days after last ceftobiprole dose visits in the Intent-to-Treat (ITT) population
| Participants | Pre-term Neonates | Term Neonates |
|---|---|---|
| EoT — Cure | 4 | 2 |
| EoT — Failure | 0 | 1 |
| EoT — Unevaluable | 2 | 0 |
| TOC — Cure | 4 | 2 |
| TOC — Failure | 0 | 1 |
| TOC — Unevaluable | 2 | 0 |
Improved signs and symptoms of LOS (including fever, hypothermia, abnormal heart rate, signs of impaired circulation, petechial rash or sclerema neonatorum, respiratory distress, gastrointestinal distress, irritability, lethargy and/or muscular or arterial hypotonia) assessed at Day 3, EOT, and TOC visits (ITT) populations.
| Participants | Pre-term Neonates | Term Neonates |
|---|---|---|
| Day 3 — Resolved | 1 | 1 |
| Day 3 — Improved | 1 | 0 |
| Day 3 — Unchanged | 3 | 1 |
| Day 3 — Worsened | 0 | 1 |
| Day 3 — Not done | 1 | 0 |
| EOT — Resolved | 1 | 1 |
| EOT — Improved | 1 | 0 |
| EOT — Unchanged | 2 | 1 |
| EOT — Worsened | 1 | 0 |
| EOT — Not done | 1 | 1 |
| TOC — Resolved | 2 | 2 |
| TOC — Improved | 2 | 0 |
| TOC — Unchanged | 1 | 0 |
| TOC — Worsened | 1 | 1 |
| TOC — Not done | 0 | 0 |
Microbiological eradication or presumed eradication rate at the EOT and TOC visits.
| Participants | Pre-term Neonates | Term Neonates |
|---|---|---|
| EOT — Eradication | 4 | 1 |
| EOT — Presumed eradication | 0 | 1 |
| EOT — Persistence | 0 | 1 |
| EOT — Unevaluable | 2 | 0 |
| TOC — Eradication | 4 | 1 |
| TOC — Presumed eradication | 0 | 1 |
| TOC — Persistence | 0 | 1 |
| TOC — Unevaluable | 2 | 0 |
Collected over Up to 5-7 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pre-term Neonates | 0/6 (0%) | 1/6 (16.7%) | 3/6 (50%) |
| Term Neonates | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Event | Pre-term Neonates | Term Neonates |
|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 0/6 | 1/3 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/6 | 1/3 |
| Enterobacter sepsisInfections and infestations | 0/6 | 1/3 |
| Intestinal obstructionGastrointestinal disorders | 1/6 | 0/3 |
| Event | Pre-term Neonates | Term Neonates |
|---|---|---|
| ThrombocytosisBlood and lymphatic system disorders | 0/6 | 1/3 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/6 | 1/3 |
| Adrenal haemorrhageEndocrine disorders | 0/6 | 1/3 |
| Vena cava thrombosisVascular disorders | 0/6 | 1/3 |
| OedemaGeneral disorders | 2/6 | 0/3 |
| Withdrawal syndromeGeneral disorders | 0/6 | 1/3 |
| Intraventricular haemorrhage neonatalNervous system disorders | 1/6 | 0/3 |
| Bronchopulmonary dysplasiaRespiratory, thoracic and mediastinal disorders | 1/6 | 0/3 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/6 | 0/3 |
| HyponatraemiaMetabolism and nutrition disorders | 1/6 | 0/3 |
| Age, Continuous(Days) | Pre-term Neonates | Term Neonates | Total |
|---|---|---|---|
| Mean | 19.2 ± 11.05 | 26.7 ± 4.51 | 21.7 ± 9.77 |
| Sex: Female, Male(Participants) | Pre-term Neonates | Term Neonates | Total |
|---|---|---|---|
| Female | 3 | 1 | 4 |
| Male | 3 | 2 | 5 |
| Ethnicity (NIH/OMB)(Participants) | Pre-term Neonates | Term Neonates | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 5 | 3 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Pre-term Neonates | Term Neonates | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 5 | 3 | 8 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(participants) | Pre-term Neonates | Term Neonates | Total |
|---|---|---|---|
| United States | 2 | 0 | 2 |
| Poland | 0 | 1 | 1 |
| Bulgaria | 2 | 1 | 3 |
| Lithuania | 0 | 1 | 1 |
| Estonia | 2 | 0 | 2 |
| Gestational age(Weeks) | Pre-term Neonates | Term Neonates | Total |
|---|---|---|---|
| Mean | 28.5 ± 4.68 | 39.0 ± 1.73 | 32.0 ± 6.48 |
| Baseline weight(gram) | Pre-term Neonates | Term Neonates | Total |
|---|---|---|---|
| Mean | 1429.2 ± 777.49 | 3156.7 ± 1094.36 | 2005.0 ± 1193.01 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2023 to primary completion in Dec 2024, 16 months.
Results were first posted in Jul 2025, 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ceftobiprole medocaril